Drivers of depression and anxiety in US segmental vitiligo patients

Babak Mohit1; Sean Fleming1; Joanna Brady1; Simran Marwaha2; Jenny Austin2; Emily Quinones2; Chloe Middleton-Dalby2
1Merck & Co., Inc., Rahway, NJ USA; 2Adelphi Real World, Bollington, UK

Background

- Segmental vitiligo (SV) is an immune-mediated disorder of partial depigmentation that most often characterized by prominent white patches on the skin.
- While SV is predominantly defined by its cosmetic presentation, it can be detrimental to patients' psychosocial health, with over half of all SV-diseased patients experiencing feelings of depression and anxiety.1
- There is limited real-world evidence investigating the burden of disease in patients with vitiligo in the United States (US).2
- In this study, we used a machine learning technique to explore the multidimensional factors, beyond clinical features, that may be associated with feelings of depression and anxiety in SV patients.

Methods

- **Data source**
  - Data were drawn from the Adelphi Vitiligo Disease Specific Programme (DSP)3, 4, a cross-sectional survey (from October 2021 to April 2022) of dermatologists and their adult and adolescent SV patients in the US.
  - Dermatologists reported patient demographics and clinical characteristics, including assessment of patient's current severity and treatment history, for their next 8 consulting SV patients (6 adults, and 2 adolescents aged 12-17 years).
- **Analysis**
  - The HBDS-12 and HBDS-29 scoring tools were used to gauge the severity of anxiety and depression symptoms, respectively.
  - **Results**
    - **Demographics**
      - **Table 1** shows the proportion of patients across all characteristics and their associated scores.
    - **Table 2** presents the top 20 predictors of HADS depression and anxiety from the elastic net regression analysis.
    - **Figure 4** displays the scatterplot for the HADS depression and anxiety scores, showing the relationship between the two variables.

Disclosures

- Merck and Co., Inc. funded the original survey through either contribution to the design of the study or by providing access to Adelphi's proprietary database. Other than the above funding, no additional support was provided from Merck or any third parties. The information provided is the property of Merck and Co., Inc.

References


1Merck & Co., Inc., Rahway, NJ USA; 2Adelphi Real World, Bollington, UK

Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.